Zetia Pre-Surgery Hold Window: What Clinicians and Patients Need to Know About Ezetimibe Before an Operation

Why the Pre-Surgery Hold Question Matters for Ezetimibe

Ezetimibe occupies an unusual place in perioperative pharmacology. Statins have explicit hold-or-continue recommendations debated across cardiology and anesthesia literature. Ezetimibe does not. Clinicians therefore get inconsistent instructions from hospitalists, surgeons, and cardiologists, and patients arrive at pre-admission testing holding a drug they did not need to stop, or continuing one they probably should have paused for gut-motility reasons.

The stakes are real for post-ACS patients, who make up a large fraction of ezetimibe users. IMPROVE-IT enrolled 18,144 patients stabilized after an acute coronary syndrome and showed that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite primary endpoint (cardiovascular death, major coronary event, or nonfatal stroke) by 6.4% relative risk reduction over a median of 6 years, with LDL-C falling from a median of 69.5 mg/dL at baseline to 53.7 mg/dL in the combination arm [1]. Abruptly stopping any lipid-lowering agent in that population is not a decision to take without a clinical rationale.

The Pharmacokinetics Behind Any Reasonable Hold Decision

Ezetimibe is absorbed in the proximal small intestine, conjugated to an active glucuronide (ezetimibe-glucuronide) in the intestinal wall and liver, and undergoes extensive enterohepatic recycling [2]. The plasma half-life of the parent compound is roughly 22 hours, but the glucuronide active metabolite extends effective cholesterol-lowering activity beyond that single half-life [2]. A 24-hour hold therefore does not fully clear the drug's biological effect; a 48- to 72-hour hold comes closer to functional washout.

This extended enterohepatic cycling is why some anesthesiologists prefer a 48-hour hold before procedures involving prolonged bowel manipulation or hepatic surgery: they want a predictable, mostly drug-free gut milieu.

What "No Mandatory Hold" Actually Means

Saying there is no mandatory hold does not mean continuing ezetimibe is always correct. It means no Level I or Level II evidence exists either way. The American College of Cardiology / American Heart Association 2022 Perioperative Guideline [3] addresses statins (continue perioperatively in patients already on them), beta-blockers, ACE inhibitors, and antiplatelet agents at length. Ezetimibe is not separately discussed, which itself is informative: the writing committee did not identify enough signal to warrant specific guidance.

The European Society of Cardiology 2022 guidelines on cardiovascular assessment before non-cardiac surgery similarly focus statin perioperative advice on the pleiotropic anti-inflammatory benefits of statins rather than on pure LDL lowering, and do not assign ezetimibe a dedicated hold class [4].

Ezetimibe Mechanism and Why It Differs from Statins Perioperatively

Statins inhibit hepatic HMG-CoA reductase. Withdrawal produces a rebound upregulation of that enzyme, which can transiently worsen LDL-C levels and, in susceptible patients, may contribute to plaque instability. Ezetimibe works entirely differently. It blocks the NPC1L1 cholesterol transporter in the brush border of the small intestine, reducing dietary and biliary cholesterol absorption by roughly 54% [5].

No Rebound Phenomenon With Ezetimibe

Because ezetimibe does not touch hepatic enzyme activity, abrupt discontinuation does not trigger the enzymatic rebound seen with statins. LDL-C simply drifts back toward baseline over several days as dietary cholesterol absorption resumes. A 2009 pharmacodynamic analysis published in the Journal of Lipid Research confirmed that NPC1L1 inhibition is fully reversible without overshoot, meaning cholesterol absorption returns to pre-treatment rates rather than surging above them [6].

This reversibility is clinically meaningful: for elective surgery with a planned 48- to 72-hour NPO window, the LDL-C elevation incurred by holding ezetimibe is modest and temporary.

Hepatic Considerations

Ezetimibe is metabolized hepatically, and the FDA-approved label notes that the drug should not be used in patients with moderate or severe hepatic impairment [7]. For patients undergoing hepatic resection, liver transplant workup, or procedures that may temporarily impair hepatic perfusion, holding ezetimibe is a reasonable pharmacokinetic precaution regardless of the absence of a formal guideline mandate.

The FDA label also flags an interaction with cyclosporine, which increases ezetimibe AUC by approximately 3.4-fold [7]. Transplant patients on cyclosporine who also take ezetimibe represent a distinct perioperative subgroup; their anesthesia team should be explicitly informed of this drug-drug interaction before any procedure.

The IMPROVE-IT Evidence Base and Its Surgical Implications

IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) was published in the New England Journal of Medicine in 2015 and remains the only large-scale mortality-relevant outcomes trial for ezetimibe [1]. Understanding it helps frame perioperative risk.

Trial Design and Key Numbers

IMPROVE-IT randomized 18,144 patients with recent ACS (within 10 days of hospitalization) to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. Median follow-up was 6 years. The primary composite endpoint occurred in 32.7% of the combination group versus 34.7% of the monotherapy group, an absolute risk reduction of 2.0 percentage points and a hazard ratio of 0.936 (95% CI 0.89 to 0.99; P<0.001 for the prespecified non-inferiority boundary; P=0.016 for superiority) [1].

LDL-C achieved in the combination arm was 53.7 mg/dL, versus 69.5 mg/dL in the simvastatin-alone arm [1]. Each 1 mmol/L (38.7 mg/dL) reduction in LDL-C is associated with approximately a 21% proportional reduction in major vascular events, per the Cholesterol Treatment Trialists' Collaboration meta-analysis of 26 trials [8].

Why Post-ACS Patients Scheduled for Surgery Need a Tailored Plan

Post-ACS patients on ezetimibe often have an LDL-C near 50 to 55 mg/dL. Surgery, particularly major cardiac or vascular procedures, generates substantial inflammatory stress. A brief rise in LDL-C from holding ezetimibe may be pharmacologically tolerable in most patients, but the cardiovascular team should be looped in for any post-ACS patient within 12 months of their event undergoing non-emergency surgery.

The ACC/AHA 2022 perioperative guideline assigns a Class IIa recommendation (Level of Evidence B-NR) to continuing statin therapy in patients undergoing non-cardiac surgery who are already on a statin for ASCVD risk [3]. By extension, that same logic supports not holding ezetimibe without a specific reason in high-risk patients.

Standard Institutional Hold Windows: What the Data Support

No randomized perioperative trial specific to ezetimibe exists as of January 2025. The following practice patterns are derived from pharmacokinetic reasoning, institutional protocols, and expert consensus, not from dedicated RCTs.

The 24-Hour Hold

A 24-hour hold before elective surgery is the most common practice in U.S. Academic medical centers. It aligns with NPO (nil per os) guidelines and the practical reality that most patients stop all oral medications at midnight the night before surgery. Pharmacokinetically, one 22-hour half-life will reduce plasma ezetimibe concentrations by roughly 50%, but enterohepatic recycling means functional cholesterol-absorption inhibition remains partially active.

The 48- to 72-Hour Hold

Some institutions, particularly those performing hepato-pancreato-biliary surgery, abdominal organ transplant, or prolonged colorectal procedures, prefer a 48- to 72-hour hold. The rationale: minimize any variable affecting bile acid and lipid metabolism in a gut that will be manipulated, resected, or re-anastomosed. A 2019 review in the British Journal of Anaesthesia [9] covering lipid-modifying drugs in the perioperative period noted that ezetimibe's enterohepatic cycle makes it behaviorally distinct from statins or fibrates and suggested individualized hold decisions for complex abdominal surgery.

Procedures Where Continuation Is Reasonable

Minor outpatient procedures (colonoscopy, upper endoscopy, dermatologic surgery, cataract extraction) do not require ezetimibe discontinuation. The patient typically resumes oral intake within hours. Holding the drug adds no safety benefit and creates a gap in LDL control that is particularly undesirable in high-risk patients.

The American Society for Gastrointestinal Endoscopy's medication management guidelines do not list ezetimibe among drugs requiring pre-procedural hold [10]. For endoscopy specifically, continuation is appropriate.

Drug Interactions Relevant to the Perioperative Setting

The table below summarizes perioperative drug interactions with ezetimibe that anesthesia and surgical teams should review during pre-admission assessment.

| Co-administered Agent | Direction of Interaction | Clinical Relevance Perioperatively | |---|---|---| | Cyclosporine | Increases ezetimibe AUC ~3.4-fold | Transplant patients: dose review before any surgery | | Fenofibrate | Increases ezetimibe AUC ~1.5-fold | Lipid-lowering combination; hold fenofibrate per its own 24-hour guideline | | Cholestyramine (bile-acid sequestrant) | Decreases ezetimibe AUC ~55% | Separate doses by 2+ hours; sequestrant rarely continued perioperatively | | Warfarin | Possible modest INR increase | Monitor INR closely; not a reason to hold ezetimibe alone | | Simvastatin / atorvastatin (fixed combo Vytorin) | Statin component drives most interaction concerns | Apply statin-hold logic to the statin component |

Sources: FDA prescribing information for ezetimibe [7]; ACC/AHA 2022 perioperative guideline [3].

Resumption After Surgery: Timing and Criteria

When to Restart

Ezetimibe should be restarted as soon as the patient tolerates oral medications reliably, typically within 24 to 48 hours postoperatively. Because it works in the intestinal lumen, meaningful cholesterol-absorption inhibition requires adequate oral intake and gut motility. Restarting it while the patient is still NPO with a nasogastric tube on suction has no pharmacological benefit.

For post-ACS patients in the IMPROVE-IT profile, rapid resumption is the appropriate goal. The 2.0 percentage point absolute risk reduction seen over 6 years [1] implies that weeks of un-necessary drug discontinuation meaningfully erode long-term benefit.

Special Cases: Hepatic Surgery and GI Anastomosis

After hepatic resection or major small-bowel surgery, the enterohepatic recycling apparatus may be transiently disrupted. Resumption at 48 to 72 hours postoperatively is reasonable once hepatic function markers (ALT, AST, total bilirubin) are trending toward normal. The FDA label contraindicates ezetimibe in active hepatic disease [7]; a brief extension of the hold until liver enzymes stabilize is clinically appropriate after hepatic procedures.

After ileal resection or terminal ileum Crohn's disease resection, NPC1L1 expression may be altered. Consult gastroenterology about the adequacy of ezetimibe-based lipid control in these patients, as absorption kinetics may shift substantially.

Ezetimibe in Combination Products: Vytorin and Liptruzet

Approximately one-third of ezetimibe prescriptions in the United States are dispensed as fixed-dose combinations: Vytorin (ezetimibe/simvastatin) and Liptruzet (ezetimibe/atorvastatin) [11]. The perioperative hold decision for these products must account for both components.

Simvastatin Component (Vytorin)

Simvastatin 40 mg has a short half-life of roughly 3 hours for the active acid form [12]. From a pure PK standpoint, a 12-hour hold before surgery would clear most active simvastatin. However, ACC/AHA 2022 recommends continuing statins perioperatively in patients already on them for ASCVD indications [3], so there is no pharmacological or guideline reason to hold Vytorin before most surgeries simply because it contains a statin.

Atorvastatin Component (Liptruzet)

Atorvastatin has a longer effective half-life (14 hours) and carries evidence for perioperative cardiac protection in vascular surgery patients, as shown in the DECREASE-III trial (N=497), where perioperative atorvastatin reduced the composite of cardiovascular death and MI from 10.8% to 4.9% (HR 0.47; P<0.001) [13]. For Liptruzet, continuation through elective surgery is strongly supported by the statin-component evidence.

Patient Counseling Points for the Pre-Admission Visit

Patients frequently receive contradictory instructions about lipid-lowering drugs from different members of their care team. A clear script reduces medication errors.

What to Tell a Low-to-Moderate Cardiovascular Risk Patient

Hold ezetimibe the morning of surgery. Restart it when you can eat and drink normally. Missing one to three doses will not meaningfully change your cholesterol levels or your surgical outcome.

What to Tell a Post-ACS or High ASCVD Risk Patient

Do not stop ezetimibe more than 48 hours before surgery without speaking to your cardiologist. The drug reduces your risk of heart attack and stroke, and stopping it longer than needed is not supported by evidence. Restart it with your first full meal after surgery.

What to Tell a Hepatic Surgery Patient

Your surgeon and hepatologist will decide when to restart ezetimibe based on your liver function tests after the procedure. The drug is processed by the liver, and your team will confirm it is safe to resume before you take it again.

Current Clinical Updates on Ezetimibe (2023 to 2025)

Generic Availability and Prescribing Patterns

The ezetimibe patent expired in 2017. As of 2024, multiple generic formulations are FDA-approved, and the drug costs under $15 per month for most patients on generic plans [14]. This price shift has expanded prescribing, meaning more patients across a wider risk spectrum arrive for surgery on ezetimibe.

ACC 2023 Expert Consensus on LDL Lowering

The ACC 2023 Expert Consensus Decision Pathway on the management of ASCVD risk affirms ezetimibe as the preferred second-line agent after maximally tolerated statin therapy, before escalation to PCSK9 inhibitors [15]. The document explicitly notes that patients achieving LDL-C <70 mg/dL on statin plus ezetimibe may not need a PCSK9 inhibitor, reducing overall drug cost and injection burden. For the perioperative context, this guideline reinforces ezetimibe's role as a long-term cardiovascular drug, not a supplement that can be casually withheld.

PCSK9 Inhibitor Comparison

Alirocumab (Praluent) and evolocumab (Repatha) reduce LDL-C by 50 to 60% and have dedicated perioperative guidance: subcutaneous injections can simply be delayed by up to 2 weeks without pharmacological harm, given their 2- to 4-week dosing interval. Ezetimibe, as a daily oral agent with a 22-hour half-life, does not share this flexibility, but also does not share the injection-site considerations that prompt the PCSK9 inhibitor hold discussion.

Summary of Recommended Perioperative Actions by Procedure Type

| Procedure Category | Recommended Hold | Resumption Timing | |---|---|---| | Minor outpatient (endoscopy, dermatologic, cataract) | None | Continue without interruption | | Elective general surgery (laparoscopic cholecystectomy, hernia repair) | 24 hours (morning of surgery) | Restart with first full meal, typically postoperative day 1 | | Major abdominal / colorectal surgery | 48 to 72 hours | Restart when bowel function returns and oral intake is established | | Hepatic resection / liver transplant workup | 48 to 72 hours; extend if LFTs abnormal | Restart once AST/ALT trending toward normal | | Cardiac surgery (CABG, valve) | Continue unless combined with statin already held | Restart with first oral medications postoperative day 1 | | Post-ACS patient, any elective procedure | Minimize hold to 24 hours; notify cardiologist | Restart at first oral intake postoperatively |